Pfizer reported results of the EMBARK trial testing Xtandi+Lupron or Xtandi alone against Lupron+Placebo. Seems that hormone-sensitive patients may be able to choose Xtandi alone and avoid Lupron. This applies to patients who had no metastases on CT/bone scan. Pfizer writes:
The study also met a key secondary endpoint with a statistically significant and clinically meaningful improvement in MFS [Metastases free survival] for patients treated with XTANDI monotherapy versus placebo plus leuprolide.